Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument

NEW YORK — DiaSorin said Wednesday the US Health and Human Services Biomedical Advanced Research Development Authority is providing $31 million toward the company's development and validation of a point-of-care instrument to provide rapid and decentralized molecular diagnostics at reduced cost.

The Saluggia, Italy-based firm said BARDA is supporting the development and Food and Drug Administration 510(k) clearance of a CLIA-waived instrument, the Liaison NES, as well as the development of an initial combination test for SARS-CoV-2 and influenza A and B viruses. The company did not disclose other terms of the agreement.

DiaSorin said the Liaison NES is designed to let untrained operators test for viral and bacterial pathogens on an easy-to-use instrument and receive results in about 15 minutes. The company said other features include a long shelf life for assay materials at room temperature and cloud-based medical data sharing.

DiaSorin said the instrument will improve access to testing and help combat the spread of new and emerging pathogens, and the company plans to develop additional assays for respiratory infections and sexually transmitted diseases, and other indications.

BARDA has previously awarded DiaSorin funding for other infectious disease assays, including COVID-19 and influenza kits for use on the company's Liaison MDX platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.